Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Watch
Primary summary from verified readiness
- Confidence
- 81% · stale
- Computed at
- 2026-09-30T21:52:27.614968+00:00
- Claimed
- 55
- Reported
- 45
- Verified
- 45
- Gap
- +10
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Agent-assisted assessment · independently reviewed · 2026-09-30
An approved option for its defined melanoma indication, with confirmatory benefit still pending.
- Why
- FDA-reviewed evidence demonstrates responses in a subset of patients, but accelerated approval rests on a single-arm study and requires confirmation of clinical benefit.
- Next
- Track IGNYTE-3, post-approval safety and treatment-center experience; clinical use should follow the approved indication and prescribing information.
Constraints
Blockers
- Comparative clinical benefit and survival improvement remain unconfirmed.
- Intratumoral administration requires suitable lesions and trained treatment teams.
- Herpetic infection, accidental exposure and injection-procedure risks require management.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 8
- Tier 1
- 4
- Tier 2
- 4
- Tier 3
- 0
- Supports
- 4
- Contradicts
- 2
- Context
- 2
- Latest observed
- 2026-08-06
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Revision 3
- 2026-08-17 Reading moved from mature to mature.
- 2026-09-22 Reading moved from mature to mature.
- 2026-09-30 Reading moved from mature to watch.